BERKELEY HEIGHTS, N.J., June 02, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will present a corporate overview at two investor conferences in June.
Jefferies 2016 Healthcare Conference
Location: The Grand Hyatt New York, New York City
Presentation date and time: Tuesday, June 7, at 8:30 a.m. Eastern Time
JMP Securities Life Sciences Conference
Location: The St. Regis New York, New York City
Presentation date and time: Wednesday, June 22, at 11 a.m. Eastern Time
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. (Edge) is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening neurological conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. For additional information about Edge, please visit www.edgetherapeutics.com.
Any statements in this press release that are not historical in nature contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge’s control) as described under the heading “Risk Factors” in Edge’s filings with the United States Securities and Exchange Commission. Edge assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.
Investor Contact: Andrew J. Einhorn Edge Therapeutics, Inc. Tel: 1-800-208-EDGE (3343) Email: firstname.lastname@example.org Media Contact: Laura Bagby 6 Degrees Tel: 312-448-8098 Email: email@example.com
Source:Edge Therapeutics, Inc.